Andere talen Editas Medicine, Inc.

Aandelen

EDIT

US28106W1036

Beurs gesloten - Nasdaq Andere beurzen 22:00:00 19-04-2024			Variatie 5 dagen	Verschil t.o.v. 1 jan (%)
5,49 ^USD	-1,08%		-11,59%	-45,80%

13/03	Transcript : Editas Medicine, Inc. Presents at Barclays 26th Annual Global Healthcare Conference 2024, Mar-13-2024 02:05 PM
29/02	EDITAS MEDICINE, INC. : Barclays is Neutraal gestemd over aandeel	ZM

Andere talen

Krijg toegang tot al het nieuws over alle bedrijven: mis nooit meer een winstgevende beleggingskans!

Gratis inschrijven

Editas Medicine : April 2024 Corporate Presentation	12/04
Editas Medicine : Corporate Effectiveness Report April 2024	12/04
Editas: Q4 Earnings Snapshot	28/02
Editas Medicine Announces Fourth Quarter and Full Year 2023 Results and Business Updates	28/02
Editas Medicine Announces Fourth Quarter and Full Year 2023 Results and Business Updates	28/02
Editas Medicine, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	28/02
Editas Medicine, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	28/02
Editas Medicine Announces Fourth Quarter and Full Year 2023 Results Conference Call and Upcoming Investor Events	21/02
Editas Medicine Announces Fourth Quarter and Full Year 2023 Results Conference Call and Upcoming Investor Events	21/02
North American Morning Briefing : Stock Futures -2-	21/02
Editas Medicine to Participate in Upcoming Investor Conferences	31/01
Editas Medicine to Participate in Upcoming Investor Conferences	31/01
Editas Medicine Highlights 2024 Anticipated Milestones and Strategic Priorities at the J.P. Morgan Healthcare Conference	08/01
Editas Medicine Highlights 2024 Anticipated Milestones and Strategic Priorities at the J.P. Morgan Healthcare Conference	08/01
Editas Medicine to Present at the 42nd Annual J.P. Morgan Healthcare Conference	03/01
Editas Medicine Strikes License Deal With Vertex Pharmaceuticals -- Update	13/12
Editas Medicine Enters Licensing Deal With Vertex Pharmaceuticals for Cas9	13/12
Editas Medicine Strikes License Deal With Vertex Pharmaceuticals	13/12
Editas Medicine and Vertex Pharmaceuticals Enter into Non-exclusive License Agreement for Cas9	13/12
Editas Medicine and Vertex Pharmaceuticals Enter into Non-exclusive License Agreement for Cas9	13/12

Geen resultaten voor deze zoekopdracht

Al het nieuws Aanbevelingen van analisten Belangrijkste gebeurtenissen Insiders Transcripties Persberichten Officiële publicaties Andere talen Ideeën voor de handel MarketScreener-artikels MarketScreener-analyses

Andere talen Editas Medicine, Inc.

Aandelen

EDIT

US28106W1036

Andere talen

Filters